ENMD-2076 tartrate structure
|
Common Name | ENMD-2076 tartrate | ||
|---|---|---|---|---|
| CAS Number | 1453868-32-0 | Molecular Weight | 525.557 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H31N7O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ENMD-2076 tartrateA multitargeted kinase inhibitor with IC50s of 3/14/23/40 nM for Flt3/Aurora A/Src/VEGFR2. |
| Name | ENMD-2076 |
|---|---|
| Synonym | More Synonyms |
| Description | A multitargeted kinase inhibitor with IC50s of 3/14/23/40 nM for Flt3/Aurora A/Src/VEGFR2. |
|---|---|
| In Vitro | A multitargeted kinase inhibitor with IC50s of 3/14/23/40 nM for Flt3/Aurora A/Src/VEGFR2; also inhibits Aurora B, c-Kit, FGFR1 (IC50=100-350 nM); orally bioactive.Liver CancerPhase 2 Clinical |
| Molecular Formula | C25H31N7O6 |
|---|---|
| Molecular Weight | 525.557 |
| Exact Mass | 525.233582 |
| InChIKey | KGWWHPZQLVVAPT-STTJLUEPSA-N |
| SMILES | Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1.O=C(O)C(O)C(O)C(=O)O |
| ENMD-2076 |
| MFCD18074523 |
| KXQ762CQTH |
| (2R,3R)-2,3-Dihydroxysuccinic acid - 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylvinyl]-4-pyrimidinamine (1:1) |
| Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-, compd. with 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]-4-pyrimidinamine (1:1) |
| MFCD18633211 |